Novo Nordisk Abandons Rare-Disease Factory for Warehouse Push as Canada Opens Door to Semaglutid Generics

Dr. Reddy's launches generic semaglutide in Canada, breaching Novo Nordisk's exclusivity. Novo shifts $1.33B plant to warehouse, as adjusted revenue dips 4% despite strong headline numbers.

The first generic version of semaglutid has landed in a G7 market, forcing Novo Nordisk to juggle intensifying price competition with the operational scramble to keep its GLP-1 blockbusters flowing. Dr. Reddy’s Laboratories launched a generic semaglutid injection in Canada on May 16, shortly after Health Canada approved it in late April. The copycat targets type 2 diabetes in two pen strengths, stopping short of the obesity segment but marking a clear breach in the Danish drugmaker’s exclusivity wall.

Novo Nordisk is already reshaping its physical footprint to defend its metabolic franchise. A planned 1.33-billion-dollar production plant in Odense, originally intended for rare-disease therapies, has been scrapped. Instead, the company will convert the site into a large warehouse to support the supply chain for Wegovy and Ozempic. The decision, which eliminates an estimated 400 new jobs, underscores how surging demand for GLP-1 drugs now dictates every capital allocation. The project’s transformation from high-tech factory to logistics hub is a blunt admission that production capacity remains the bottleneck.

That operational focus comes at a time when the headline numbers tell a deceptively strong story. Novo Nordisk reported first-quarter revenue of 96.8 billion Danish kroner, up 24 percent, with net profit of 48.6 billion kroner. Yet the top line was inflated by a massive, non-cash reversal of provisions in the US market. Stripping out that one-time effect, adjusted revenue actually shrank 4 percent in constant currencies. Despite the underlying dip, management raised its full-year guidance, betting that the production ramp will eventually offset the margin pressure.

Canada’s generic entry is the most tangible sign yet that the GLP-1 gold rush is attracting serious copycat competition. In India, where the patent lapsed earlier this year, a flurry of local alternatives emerged. Canada matters more because it is a highly regulated industrial market, and Dr. Reddy’s move could set a precedent for other developed nations. The broader threat is amplified by a pipeline of new entrants: Eli Lilly remains the primary rival, reporting first-quarter revenue of 19.8 billion dollars for a 55.5 percent growth rate, while Pfizer and Roche are also advancing their own candidates.

The stock market is weighing all these forces with caution. Shares closed Friday at 38.56 euros, down 1.82 percent on the day. The monthly performance shows a gain of 11.72 percent, but that rally has failed to reverse deeper damage. The stock is down 13.7 percent year-to-date and has shed 34.93 percent over the past twelve months. It still trades below its long-term average of 42.38 euros, a level that served as a psychological anchor before the recent volatility. For comparison, a consensus of analysts sees a target of 65.56 dollars per share, though the majority rating is “Hold” with only scattered buy recommendations.

With the original semaglutid facing growing price comparisons, Novo Nordisk’s next big hope lies in its pipeline. The company is pushing forward with cagrilintid, a weekly injectable that regulates appetite and energy intake. Positive phase 2 data would provide a fresh narrative — and potentially new pricing power — against the generics beginning to nibble at the edges of the first-generation GLP-1 franchise. At the same time, the oral GLP-1 program is advancing to secure longer-term differentiation in a market where Novo Nordisk can no longer count on patent protection alone.

The strategic calculus has become a tightrope act. Novo Nordisk must rapidly expand production in Denmark and the US while navigating reimbursement hurdles and pricing risks, particularly in the critical US market. Failure to execute could accelerate market share losses to a swelling competitive field. For now, the company is betting that volume growth from Wegovy and Ozempic will outweigh the margin erosion — and that a repurposed warehouse in Odense will help deliver on that promise.